ABOUT US
With a Vision of Making Quality Healthcare Affordable Through Drug Delivery Solutions Focusing On Patient Convenience and Adherence, ZIM’s value propositions is its ability to provide a range of technology-based drug delivery solutions and non-infringing proprietary manufacturing processes for development, manufacture and supply of innovative and differentiated generic pharmaceutical products to its customers globally.
OUR VALUES
Zeal
It is our only passion that will fuel our drive for excellence in product quality, affordability and marketability.
Challenging the Status Quo
Through relentless pursuit of excellence and encouraging innovation, which is the foundation of our success.
Integrity
Stringent adherence to the moral and ethical code of the company, including transparency, open communication channels and impartiality to make every member feel valued.
Skill Improvement
Continuous training and upgrading of employee skills and competencies of our team, to provide zero-defect, effective medicines to our patients.
Concern for Environment
Ensure judicious use and protection of the country’s resources by minimizing waste, thereby reducing the burden of cost of maintenance of such natural resources for future generations.
Empathy
Promote a sense of compassion among all members of the organization for the health and wellbeing of the common man, spurring each one to provide them with high quality affordable medicines.
Kindness
There is always a good and pleasant way of saying and doing things in all our interactions with colleagues, clients and others we meet at our work place. This is way we expect others to treat us.
Fairness
A fair treatment to all is the best way to create & retain our goodwill and the trust of our business associates and colleagues.
Zim Labs has technology backed solutions that enables catering across various therapeutic segments such as
Cardiovascular
Anti-infective
Gastrointestinal
Respiratory system
Nervous system
Musculoskeletal
Haematology system
Vitamins
Our innovative technology solutions include drug release profile modifications, solubility & stability enhancement, taste masking and dosage form transformation
HISTORY & PATH FORWARD
An overview of Zim Labs at a glance from its inception, current offerings to its path forward and the leadership behind the journey.
1989
Establishment of Company and
first manufacturing site.
1993
WHO GMP Status and maiden
public issue.
2000
Pellets Technology
developed.
2005
Taste Masking
Technology Introduced.
2010
New Cephalosporin
Block Added.
2013
New Orally Disintegrating Strip (ODS)
Manufacturing Block Added.
2014
WHO-GMP Status for Orally Disintegrating Strip Mfg. Facility.
2015
EUGMP
Accreditation.
2018
EUGMP Audit Cleared Successfully by "EUGMP RE-ACCREDITED."
2000
Leading supplier of pharmaceutical
products to government organizations through tenders from its WHO-GMP approved plant.
2001-2012
Developed Pellets, Granules and
Taste Masking Technology Platforms to change its focus to differentiated and higher margin products. Ventured into international markets in Middle East and North Africa (MENA). Established ‘Proof-of-Concept’ for Oral Thin Films and Nano-technology.
2012 - 2017
Funding from private
equity investor; focus on higher margin businesses; reduce deemed export and low margin government business. Upgraded its manufacturing facilities to EU-GMP standards; investment in team and processes. Invested in separate WHO-GMP approved OTF facility and commercialise OTF products. Entered into newer geographies like SEA, LatAm, CIS and Africa and grew Sri Lanka, Bangladesh and MENA. Focused on building a steady pipeline with dossier filings and own product registrations.
2018 - Future
ZIM LABORATORIES LIMITED GOT LISTED ON BOMBAY STOCK EXCHANGE
Continued focus in core PFI business through new geographies, new customer relationships and new product pipeline for its business partners. Growing its niche generic formulations business – through registration, marketing partnerships and continued launch of products in MENA, SE Asia, Latin America and CIS countries (as demonstrated in Sri Lanka). Launch of OTF (prescription and OTC products) as an alternate drug delivery platform across RoW / Emerging Markets and Regulated Markets. Invest in R&D to develop a pipeline of products with focus on developed markets and enhance capacity and flexibility by appropriate capex.
ZIM IN FOCUS
Over time ZIM has created a long term sustainable advantage by focused on Novel Drug Delivery Solutions (NDDS) segment through continuous innovation and development of non-infringing technology platforms and supply of high quality products at competitive prices.
The Company is led by an experienced technocrat who is supported by a well-qualified professional management team.
R&D capabilities & manufacturing skills to develop & supply differentiated generic products, in pre-formulation dosage forms, to business partners who need comprehensive support in product development, full mfg technical training, registration & sourcing of such differentiated products to boost their pipeline & compete.
ZIM has three manufacturing blocks (General, Cephalosporin and OTF). ZIM general block is EU-GMP and WHO-GMP approved. Its Cephalosporin and OTF blocks are WHO-GMP approved. ZIM is amongst the few companies in India to receive WHO-GMP approval for its OTF facility.
ZIM supplies a wide range of solid dosage differentiated products across various therapeutic segments. ZIM is a pioneer in the OTF technology in India and focussed on growing this platform in partnership with marketing companies and product originators.
• Developing new technology platforms & differentiated generic products for itself and under license arrangement.
• Manufacturing and supply of finished and semi-finished formulations for RoW
• Development of the Thin Film as an alternate delivery platform
ZIM has a state of the art R&D centre with a team of over 90 professionals. ZIM is now setting up a new R&D centre with team, equipment and capabilities targeted for developed markets.
The Company has improved its EBITDA Margins from 11% to 15% in last four years on account of continued focus on high margin businesses.
ACCREDITATIONS
Our facilities are accredited with respected certifications from authorized independent bodies, which are generally accepted worldwide as a mark of approval of the quality of the manufacturer’s operational capabilities. These accreditations are:
Armenia Montezim
Certificate of Vietnam
Colombia GMP Certificates
Ethiopia Notification For GMP Inspection Exemption
Ivory Coast GMP Certificate
Kenya GMP
Myanmar Levocetirizine dihydrochloride Tablets 5 mg
Nigeria GMP Certificate NAFDAC
Philippines BFAD Certificate
Russia Nebivolol Tablets
Rwanda Cefereo 250
Sri Lanka Olmesartan Medoxomil Tablets 20 mg
Tajikistan Rozastat
Turkmenistan ZIMAGRA ODS
UAE Certificate
Uganda NDA GMP Certificate
Ukraine GMP Certificate
Uzbekistan Zumalis